FAQ

Marqibo

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
01220092016

Related topics

Related topics

2 relations

Broader (2)

Vincristine sulfate liposomevincristine liposome

Related mentions per year

Related mentions per year

1990-2018
1990200020102020
Marqibo
Vincristine sulfate liposome
vincristine liposome

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
BACKGROUND Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in… (More)
  • table I
  • table III
  • table III
  • table IV
  • figure 1
Is this relevant?
2014
2014
Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative…
BACKGROUND VSLI (Marqibo) is active in advanced non-Hodgkin lymphoma (NHL) and untreated aggressive NHL. Because of its favorable… (More)
  • table 1
  • table 2
  • table 5
  • table 3
  • figure 1
Is this relevant?
2012
2012
FDA approves liposomal vincristine (Marqibo) for rare leukemia.
  • Oncology
  • 2012
 
Is this relevant?
2011
2011
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being… (More)
  • table I
  • table II
  • table III
  • table IV
Is this relevant?
2011
2011
Vincristine sulfate liposomes injection (VSLI) "bridging" to potentially curative hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome negative (Ph-) acute…
6527 Background: In a phase II, multi-national study (RALLY Trial; NCT00495079 ), 65 adults (median age 32 yrs, range 19 to 83… (More)
Is this relevant?
Review
2009
Review
2009
Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
BACKGROUND Marqibo, a sphingosomal/cholesterol encapsulation of vincristine sulfate has targeted, increased, and sustained… (More)
Is this relevant?
2009
2009
Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma.
9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in… (More)
Is this relevant?